<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">35215228</PMID><DateRevised><Year>2024</Year><Month>08</Month><Day>24</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">1424-8247</ISSN><JournalIssue CitedMedium="Print"><Volume>15</Volume><Issue>2</Issue><PubDate><Year>2022</Year><Month>Jan</Month><Day>18</Day></PubDate></JournalIssue><Title>Pharmaceuticals (Basel, Switzerland)</Title><ISOAbbreviation>Pharmaceuticals (Basel)</ISOAbbreviation></Journal><ArticleTitle>Discovery of Novel Andrographolide Derivatives as Antiviral Inhibitors against Human Enterovirus A71.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">115</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ph15020115</ELocationID><Abstract><AbstractText>Hand-foot-and-mouth disease (HFMD) caused by human enterovirus A71 (EV-A71) infection has been associated with severe neurological complications. With the lack of an internationally approved antiviral, coupled with a surge in outbreaks globally, EV-A71 has emerged as a neurotropic virus of high clinical importance. Andrographolide has many pharmacological effects including antiviral activity and its derivative, andrographolide sulfonate, has been used in China clinically to treat EV-A71 infections. This study sought to identify novel andrographolide derivatives as EV-A71 inhibitors and elucidate their antiviral mode of action. Using an immunofluorescence-based phenotypic screen, we identified novel EV-A71 inhibitors from a 344-compound library of andrographolide derivatives and validated them with viral plaque assays. Among these hits, <b>ZAF-47</b>, a quinolinoxy-andrographolide, was selected for downstream mechanistic studies. It was found that <b>ZAF-47</b> acts on EV-A71 post-entry stages and inhibits EV-A71 protein expression. Subsequent luciferase studies confirm that <b>ZAF-47</b> targets EV-A71 genome RNA replication specifically. Unsuccessful attempts in generating resistant mutants led us to believe a host factor is likely to be involved which coincide with the finding that <b>ZAF-47</b> exhibits broad-spectrum antiviral activity against other enteroviruses (CV-A16, CV-A6, Echo7, CV-B5, CV-A24 and EV-D68). Furthermore, <b>ZAF-46</b> and <b>ZAF-47</b>, hits from the screen, were derivatives of the same series containing quinolinoxy and olefin modifications, suggesting that an andrographolide scaffold mounted with these unique moieties could be a potential anti-EV-A71/HFMD strategy.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tan</LastName><ForeName>Jie Kai</ForeName><Initials>JK</Initials><Identifier Source="ORCID">0000-0002-0095-9591</Identifier><AffiliationInfo><Affiliation>Laboratory of Molecular RNA Virology and Antiviral Strategies, Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117545, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Ran</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>School of Pharmaceutical Sciences, Nanjing Tech University, Nanjing 211816, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Regina Ching Hua</ForeName><Initials>RCH</Initials><AffiliationInfo><Affiliation>Laboratory of Molecular RNA Virology and Antiviral Strategies, Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117545, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Feng</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>School of Pharmaceutical Sciences, Nanjing Tech University, Nanjing 211816, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dai</LastName><ForeName>Kun</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>School of Pharmaceutical Sciences, Nanjing Tech University, Nanjing 211816, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Guo-Chun</ForeName><Initials>GC</Initials><Identifier Source="ORCID">0000-0003-3145-223X</Identifier><AffiliationInfo><Affiliation>School of Pharmaceutical Sciences, Nanjing Tech University, Nanjing 211816, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chu</LastName><ForeName>Justin Jang Hann</ForeName><Initials>JJH</Initials><Identifier Source="ORCID">0000-0002-1673-6819</Identifier><AffiliationInfo><Affiliation>Laboratory of Molecular RNA Virology and Antiviral Strategies, Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117545, Singapore.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Infectious Disease Translational Research Programme, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117597, Singapore.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Collaborative and Translation Unit for HFMD, Institute of Molecular and Cell Biology, Agency for Science, Technology and Research, Singapore 138673, Singapore.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>30973621</GrantID><Agency>National Natural Science Foundation of China</Agency><Country /></Grant><Grant><GrantID>U0632001</GrantID><Agency>National Natural Science Foundation of China</Agency><Country /></Grant><Grant><GrantID>MOE2017-T2-2-014</GrantID><Agency>Ministry of Education</Agency><Country /></Grant><Grant><GrantID>NRF-CRP21-2018-0004</GrantID><Agency>NRF Competitive Research Programme</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>01</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Pharmaceuticals (Basel)</MedlineTA><NlmUniqueID>101238453</NlmUniqueID><ISSNLinking>1424-8247</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">andrographolide</Keyword><Keyword MajorTopicYN="N">broad-spectrum anti-enterovirus agent</Keyword><Keyword MajorTopicYN="N">host-targeting</Keyword><Keyword MajorTopicYN="N">human enterovirus A71</Keyword><Keyword MajorTopicYN="N">olefin</Keyword><Keyword MajorTopicYN="N">quinolinoxy</Keyword><Keyword MajorTopicYN="N">viral RNA replication</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>12</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>1</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>1</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>2</Month><Day>26</Day><Hour>1</Hour><Minute>5</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>2</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>2</Month><Day>27</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>1</Month><Day>18</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35215228</ArticleId><ArticleId IdType="pmc">PMC8880313</ArticleId><ArticleId IdType="doi">10.3390/ph15020115</ArticleId><ArticleId IdType="pii">ph15020115</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Patil R., Jain V. Andrographolide: A Review of Analytical Methods. J. Chromatogr. Sci. 2021;59:191–203. doi: 10.1093/chromsci/bmaa091.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/chromsci/bmaa091</ArticleId><ArticleId IdType="pubmed">33221827</ArticleId></ArticleIdList></Reference><Reference><Citation>Dai Y., Chen S.-R., Chai L., Zhao J., Wang Y., Wang Y. Overview of Pharmacological Activities of Andrographis Paniculata and Its Major Compound Andrographolide. Crit. Rev. Food Sci. Nutr. 2019;59:S17–S29. doi: 10.1080/10408398.2018.1501657.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/10408398.2018.1501657</ArticleId><ArticleId IdType="pubmed">30040451</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar G., Singh D., Tali J.A., Dheer D., Shankar R. Andrographolide: Chemical Modification and Its Effect on Biological Activities. Bioorganic Chem. 2020;95:103511. doi: 10.1016/j.bioorg.2019.103511.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bioorg.2019.103511</ArticleId><ArticleId IdType="pubmed">31884143</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang M., Sheng F., Zhang Z., Ma X., Gao T., Fu C., Li P. Andrographis Paniculata (Burm. f.) Nees and Its Major Constituent Andrographolide as Potential Antiviral Agents. J. Ethnopharmacol. 2021;272:113954. doi: 10.1016/j.jep.2021.113954.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jep.2021.113954</ArticleId><ArticleId IdType="pubmed">33610706</ArticleId></ArticleIdList></Reference><Reference><Citation>Wintachai P., Kaur P., Lee R.C.H., Ramphan S., Kuadkitkan A., Wikan N., Ubol S., Roytrakul S., Chu J.J.H., Smith D.R. Activity of Andrographolide against Chikungunya Virus Infection. Sci. Rep. 2015;5:14179. doi: 10.1038/srep14179.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep14179</ArticleId><ArticleId IdType="pmc">PMC4585663</ArticleId><ArticleId IdType="pubmed">26384169</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaushik S., Dar L., Kaushik S., Yadav J.P. Identification and Characterization of New Potent Inhibitors of Dengue Virus NS5 Proteinase from Andrographis Paniculata Supercritical Extracts on in Animal Cell Culture and in Silico Approaches. J. Ethnopharmacol. 2021;267:113541. doi: 10.1016/j.jep.2020.113541.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jep.2020.113541</ArticleId><ArticleId IdType="pubmed">33152438</ArticleId></ArticleIdList></Reference><Reference><Citation>Panraksa P., Ramphan S., Khongwichit S., Smith D.R. Activity of Andrographolide against Dengue Virus. Antivir. Res. 2017;139:69–78. doi: 10.1016/j.antiviral.2016.12.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2016.12.014</ArticleId><ArticleId IdType="pubmed">28034742</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin T.-P., Chen S.-Y., Duh P.-D., Chang L.-K., Liu Y.-N. Inhibition of the Epstein-Barr Virus Lytic Cycle by Andrographolide. Biol. Pharm. Bull. 2008;31:2018–2023. doi: 10.1248/bpb.31.2018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1248/bpb.31.2018</ArticleId><ArticleId IdType="pubmed">18981566</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu B., Dai C., Jiang Z., Li E., Chen C., Wu X., Chen J., Liu Q., Zhao C., He J., et al. Andrographolide as an Anti-H1N1 Drug and the Mechanism Related to Retinoic Acid-Inducible Gene-I-like Receptors Signaling Pathway. Chin. J. Integr. Med. 2014;20:540–545. doi: 10.1007/s11655-014-1860-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11655-014-1860-0</ArticleId><ArticleId IdType="pubmed">24972581</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen H., Ma Y.-B., Huang X.-Y., Geng C.-A., Zhao Y., Wang L.-J., Guo R.-H., Liang W.-J., Zhang X.-M., Chen J.-J. Synthesis, Structure—Activity Relationships and Biological Evaluation of Dehydroandrographolide and Andrographolide Derivatives as Novel Anti-Hepatitis B Virus Agents. Bioorganic Med. Chem. Lett. 2014;24:2353–2359. doi: 10.1016/j.bmcl.2014.03.060.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bmcl.2014.03.060</ArticleId><ArticleId IdType="pubmed">24731274</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee J.-C., Tseng C.-K., Young K.-C., Sun H.-Y., Wang S.-W., Chen W.-C., Lin C.-K., Wu Y.-H. Andrographolide Exerts Anti-Hepatitis C Virus Activity by up-Regulating Haeme Oxygenase-1 via the P38 MAPK/Nrf2 Pathway in Human Hepatoma Cells. Br. J. Pharmacol. 2014;171:237–252. doi: 10.1111/bph.12440.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bph.12440</ArticleId><ArticleId IdType="pmc">PMC3874710</ArticleId><ArticleId IdType="pubmed">24117426</ArticleId></ArticleIdList></Reference><Reference><Citation>Uttekar M.M., Das T., Pawar R.S., Bhandari B., Menon V., Nutan, Gupta S.K., Bhat S.V. Anti-HIV Activity of Semisynthetic Derivatives of Andrographolide and Computational Study of HIV-1 Gp120 Protein Binding. Eur. J. Med. Chem. 2012;56:368–374. doi: 10.1016/j.ejmech.2012.07.030.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejmech.2012.07.030</ArticleId><ArticleId IdType="pubmed">22858223</ArticleId></ArticleIdList></Reference><Reference><Citation>Niranjan Reddy V.L., Malla Reddy S., Ravikanth V., Krishnaiah P., Venkateshwar Goud T., Rao T.P., Siva Ram T., Gonnade R.G., Bhadbhade M., Venkateswarlu Y. A New BIS-Andrographolide Ether from Andrographis Paniculata Nees and Evaluation of Anti-HIV Activity. Nat. Prod. Res. 2005;19:223–230. doi: 10.1080/14786410410001709197.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14786410410001709197</ArticleId><ArticleId IdType="pubmed">15702635</ArticleId></ArticleIdList></Reference><Reference><Citation>Seubsasana S., Pientong C., Ekalaksananan T., Thongchai S., Aromdee C. A Potential Andrographolide Analogue against the Replication of Herpes Simplex Virus Type 1 in Vero Cells. Med. Chem. 2011;7:237–244. doi: 10.2174/157340611795564268.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/157340611795564268</ArticleId><ArticleId IdType="pubmed">21486208</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiart C., Kumar K., Yusof M.Y., Hamimah H., Fauzi Z.M., Sulaiman M. Antiviral Properties of Ent-Labdene Diterpenes of Andrographis Paniculata Nees, Inhibitors of Herpes Simplex Virus Type 1. Phytother. Res. 2005;19:1069–1070. doi: 10.1002/ptr.1765.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ptr.1765</ArticleId><ArticleId IdType="pubmed">16372376</ArticleId></ArticleIdList></Reference><Reference><Citation>Sa-ngiamsuntorn K., Suksatu A., Pewkliang Y., Thongsri P., Kanjanasirirat P., Manopwisedjaroen S., Charoensutthivarakul S., Wongtrakoongate P., Pitiporn S., Chaopreecha J., et al. Anti-SARS-CoV-2 Activity of Andrographis Paniculata Extract and Its Major Component Andrographolide in Human Lung Epithelial Cells and Cytotoxicity Evaluation in Major Organ Cell Representatives. J. Nat. Prod. 2021;84:1261–1270. doi: 10.1021/acs.jnatprod.0c01324.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jnatprod.0c01324</ArticleId><ArticleId IdType="pubmed">33844528</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi T.-H., Huang Y.-L., Chen C.-C., Pi W.-C., Hsu Y.-L., Lo L.-C., Chen W.-Y., Fu S.-L., Lin C.-H. Andrographolide and Its Fluorescent Derivative Inhibit the Main Proteases of 2019-NCoV and SARS-CoV through Covalent Linkage. Biochem. Biophys. Res. Commun. 2020;533:467–473. doi: 10.1016/j.bbrc.2020.08.086.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2020.08.086</ArticleId><ArticleId IdType="pmc">PMC7447262</ArticleId><ArticleId IdType="pubmed">32977949</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang D., Guo H., Chang J., Wang D., Liu B., Gao P., Wei W. Andrographolide Prevents EV-D68 Replication by Inhibiting the Acidification of Virus-Containing Endocytic Vesicles. Front. Microbiol. 2018;9:2407. doi: 10.3389/fmicb.2018.02407.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2018.02407</ArticleId><ArticleId IdType="pmc">PMC6186950</ArticleId><ArticleId IdType="pubmed">30349523</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt N.J., Lennette E.H., Ho H.H. An Apparently New Enterovirus Isolated from Patients with Disease of the Central Nervous System. J. Infect. Dis. 1974;129:304–309. doi: 10.1093/infdis/129.3.304.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/129.3.304</ArticleId><ArticleId IdType="pubmed">4361245</ArticleId></ArticleIdList></Reference><Reference><Citation>Kennett M.L., Birch C.J., Lewis F.A., Yung A.P., Locarnini S.A., Gust I.D. Enterovirus Type 71 Infection in Melbourne. Bull. World Health Organ. 1974;51:609–615.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2366271</ArticleId><ArticleId IdType="pubmed">4377551</ArticleId></ArticleIdList></Reference><Reference><Citation>Chumakov M., Voroshilova M., Shindarov L., Lavrova I., Gracheva L., Koroleva G., Vasilenko S., Brodvarova I., Nikolova M., Gyurova S., et al. Enterovirus 71 Isolated from Cases of Epidemic Poliomyelitis-like Disease in Bulgaria. Arch. Virol. 1979;60:329–340. doi: 10.1007/BF01317504.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF01317504</ArticleId><ArticleId IdType="pubmed">228639</ArticleId></ArticleIdList></Reference><Reference><Citation>Tagaya I., Takayama R., Hagiwara A. A Large-Scale Epidemic of Hand, Foot and Mouth Disease Associated with Enterovirus 71 Infection in Japan in 1978. Jpn. J. Med. Sci. Biol. 1981;34:191–196. doi: 10.7883/yoken1952.34.191.</Citation><ArticleIdList><ArticleId IdType="doi">10.7883/yoken1952.34.191</ArticleId><ArticleId IdType="pubmed">6273621</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagy G., Takátsy S., Kukán E., Mihály I., Dömök I. Virological Diagnosis of Enterovirus Type 71 Infections: Experiences Gained during an Epidemic of Acute CNS Diseases in Hungary in 1978. Arch. Virol. 1982;71:217–227. doi: 10.1007/BF01314873.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF01314873</ArticleId><ArticleId IdType="pubmed">6285858</ArticleId></ArticleIdList></Reference><Reference><Citation>Chua K.B., Chua B.H., Lee C.S.M., Chem Y.K., Ismail N., Kiyu A., Kumarasamy V. Genetic Diversity of Enterovirus 71 Isolated from Cases of Hand, Foot and Mouth Disease in the 1997, 2000 and 2005 Outbreaks, Peninsular Malaysia. Malays. J. Pathol. 2007;29:69–78.</Citation><ArticleIdList><ArticleId IdType="pubmed">19108398</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho M., Chen E.-R., Hsu K.-H., Twu S.-J., Chen K.-T., Tsai S.-F., Wang J.-R., Shih S.-R. An Epidemic of Enterovirus 71 Infection in Taiwan. N. Engl. J. Med. 1999;341:929–935. doi: 10.1056/NEJM199909233411301.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM199909233411301</ArticleId><ArticleId IdType="pubmed">10498487</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang S.-W., Hsu Y.-W., Smith D.J., Kiang D., Tsai H.-P., Lin K.-H., Wang S.-M., Liu C.-C., Su I.-J., Wang J.-R. Reemergence of Enterovirus 71 in 2008 in Taiwan: Dynamics of Genetic and Antigenic Evolution from 1998 to 2008. J. Clin. Microbiol. 2009;47:3653–3662. doi: 10.1128/JCM.00630-09.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JCM.00630-09</ArticleId><ArticleId IdType="pmc">PMC2772620</ArticleId><ArticleId IdType="pubmed">19776232</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin K.-H., Hwang K.-P., Ke G.-M., Wang C.-F., Ke L.-Y., Hsu Y.-T., Tung Y.-C., Chu P.-Y., Chen B.-H., Chen H.-L., et al. Evolution of EV71 Genogroup in Taiwan from 1998 to 2005: An Emerging of Subgenogroup C4 of EV71. J. Med. Virol. 2006;78:254–262. doi: 10.1002/jmv.20534.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.20534</ArticleId><ArticleId IdType="pubmed">16372302</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin T.-Y., Twu S.-J., Ho M.-S., Chang L.-Y., Lee C.-Y. Enterovirus 71 Outbreaks, Taiwan: Occurrence and Recognition. Emerg. Infect. Dis. 2003;9:291–293. doi: 10.3201/eid0903.020285.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid0903.020285</ArticleId><ArticleId IdType="pmc">PMC2963902</ArticleId><ArticleId IdType="pubmed">12643822</ArticleId></ArticleIdList></Reference><Reference><Citation>Hosoya M., Kawasaki Y., Sato M., Honzumi K., Kato A., Hiroshima T., Ishiko H., Suzuki H. Genetic Diversity of Enterovirus 71 Associated with Hand, Foot and Mouth Disease Epidemics in Japan from 1983 to 2003. Pediatr. Infect. Dis. J. 2006;25:691–694. doi: 10.1097/01.inf.0000227959.89339.c3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.inf.0000227959.89339.c3</ArticleId><ArticleId IdType="pubmed">16874167</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Y., Yeo A., Phoon M.C., Tan E.L., Poh C.L., Quak S.H., Chow V.T.K. The Largest Outbreak of Hand; Foot and Mouth Disease in Singapore in 2008: The Role of Enterovirus 71 and Coxsackievirus a Strains. Int. J. Infect. Dis. 2010;14:e1076–e1081. doi: 10.1016/j.ijid.2010.07.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2010.07.006</ArticleId><ArticleId IdType="pubmed">20952237</ArticleId></ArticleIdList></Reference><Reference><Citation>Chong C.Y., Chan K.P., Shah V.A., Ng W.Y.M., Lau G., Teo T.E.S., Lai S.H., Ling A.E. Hand, Foot and Mouth Disease in Singapore: A Comparison of Fatal and Non-Fatal Cases. Acta Paediatr. 2003;92:1163–1169. doi: 10.1111/j.1651-2227.2003.tb02478.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1651-2227.2003.tb02478.x</ArticleId><ArticleId IdType="pubmed">14632332</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang B., Liu F., Liao Q., Wu P., Chang Z., Huang J., Long L., Luo L., Li Y., Leung G.M., et al. Epidemiology of Hand, Foot and Mouth Disease in China, 2008 to 2015 Prior to the Introduction of EV-A71 Vaccine. Eurosurveillance. 2017;22:16–00824. doi: 10.2807/1560-7917.ES.2017.22.50.16-00824.</Citation><ArticleIdList><ArticleId IdType="doi">10.2807/1560-7917.ES.2017.22.50.16-00824</ArticleId><ArticleId IdType="pmc">PMC5743100</ArticleId><ArticleId IdType="pubmed">29258646</ArticleId></ArticleIdList></Reference><Reference><Citation>Puenpa J., Wanlapakorn N., Vongpunsawad S., Poovorawan Y. The History of Enterovirus A71 Outbreaks and Molecular Epidemiology in the Asia-Pacific Region. J. Biomed. Sci. 2019;26:75. doi: 10.1186/s12929-019-0573-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12929-019-0573-2</ArticleId><ArticleId IdType="pmc">PMC6798416</ArticleId><ArticleId IdType="pubmed">31627753</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu M.Y., Liu W., Luo J., Liu Y., Zhu Y., Berman H., Wu J. Characterization of an Outbreak of Hand, Foot, and Mouth Disease in Nanchang, China in 2010. PLoS ONE. 2011;6:e25287. doi: 10.1371/journal.pone.0025287.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0025287</ArticleId><ArticleId IdType="pmc">PMC3182205</ArticleId><ArticleId IdType="pubmed">21980416</ArticleId></ArticleIdList></Reference><Reference><Citation>Messacar K., Burakoff A., Nix W.A., Rogers S., Oberste M.S., Gerber S.I., Spence-Davizon E., Herlihy R., Dominguez S.R. Notes from the Field: Enterovirus A71 Neurologic Disease in Children—Colorado, 2018. MMWR Morb. Mortal. Wkly. Rep. 2018;67:1017–1018. doi: 10.15585/mmwr.mm6736a5.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm6736a5</ArticleId><ArticleId IdType="pmc">PMC6146947</ArticleId><ArticleId IdType="pubmed">30212441</ArticleId></ArticleIdList></Reference><Reference><Citation>Taravilla C.N., Pérez-Sebastián I., Salido A.G., Serrano C.V., Extremera V.C., Rodríguez A.D., Marín L.L., Sanz M.A., Traba O.M.S., González A.S. Enterovirus A71 Infection and Neurologic Disease, Madrid, Spain, 2016. Emerg. Infect. Dis. 2019;25:25–32. doi: 10.3201/eid2501.181089.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid2501.181089</ArticleId><ArticleId IdType="pmc">PMC6302576</ArticleId><ArticleId IdType="pubmed">30560775</ArticleId></ArticleIdList></Reference><Reference><Citation>Antona D., Kossorotoff M., Schuffenecker I., Mirand A., Leruez-Ville M., Bassi C., Aubart M., Moulin F., Lévy-Bruhl D., Henquell C., et al. Severe Paediatric Conditions Linked with EV-A71 and EV-D68, France, May to October 2016. Eurosurveillance. 2016;21:30402. doi: 10.2807/1560-7917.ES.2016.21.46.30402.</Citation><ArticleIdList><ArticleId IdType="doi">10.2807/1560-7917.ES.2016.21.46.30402</ArticleId><ArticleId IdType="pmc">PMC5144948</ArticleId><ArticleId IdType="pubmed">27918268</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X., Zhang C., Shi Q., Yang T., Zhu Q., Tian Y., Lu C., Zhang Z., Jiang Z., Zhou H., et al. Improving the Efficacy of Conventional Therapy by Adding Andrographolide Sulfonate in the Treatment of Severe Hand, Foot, and Mouth Disease: A Randomized Controlled Trial. Evid.-Based Complement. Altern. Med. 2013;2013:1–8. doi: 10.1155/2013/316250.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2013/316250</ArticleId><ArticleId IdType="pmc">PMC3557643</ArticleId><ArticleId IdType="pubmed">23401711</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang G., Hou Y., Li Y., He L., Tang L., Yang T., Zou X., Zhu Q., Yan S., Huang B., et al. Xiyanping Injection Therapy for Children with Mild Hand Foot and Mouth Disease: A Randomized Controlled Trial. J. Tradit. Chin. Med. 2017;37:397–403.</Citation><ArticleIdList><ArticleId IdType="pubmed">31682384</ArticleId></ArticleIdList></Reference><Reference><Citation>Li M., Yang X., Guan C., Wen T., Duan Y., Zhang W., Li X., Wang Y., Zhao Z., Liu S. Andrographolide Sulfonate Reduces Mortality in Enterovirus 71 Infected Mice by Modulating Immunity. Int. Immunopharmacol. 2018;55:142–150. doi: 10.1016/j.intimp.2017.11.042.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.intimp.2017.11.042</ArticleId><ArticleId IdType="pubmed">29253820</ArticleId></ArticleIdList></Reference><Reference><Citation>Min N., Leong P.T., Lee R.C.H., Khuan J.S.E., Chu J.J.H. A Flavonoid Compound Library Screen Revealed Potent Antiviral Activity of Plant-Derived Flavonoids on Human Enterovirus A71 Replication. Antivir. Res. 2018;150:60–68. doi: 10.1016/j.antiviral.2017.12.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2017.12.003</ArticleId><ArticleId IdType="pubmed">29233744</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J.-H., Chung T.D.Y., Oldenburg K.R. A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays. J. Biomol. Screen. 1999;4:67–73. doi: 10.1177/108705719900400206.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/108705719900400206</ArticleId><ArticleId IdType="pubmed">10838414</ArticleId></ArticleIdList></Reference><Reference><Citation>Dai K., Tan J.K., Qian W., Lee R.C.H., Chu J.J.H., Zhou G.-C. Discovery of 14S-(2′-Chloro-4′-Nitrophenoxy)-8R/S, 17-Epoxy Andrographolide as EV-A71 Infection Inhibitor. Biochem. Pharmacol. 2021;194:114820. doi: 10.1016/j.bcp.2021.114820.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bcp.2021.114820</ArticleId><ArticleId IdType="pubmed">34748818</ArticleId></ArticleIdList></Reference><Reference><Citation>Li F., Lee E.M., Sun X., Wang D., Tang H., Zhou G.-C. Design, Synthesis and Discovery of Andrographolide Derivatives against Zika Virus Infection. Eur. J. Med. Chem. 2020;187:111925. doi: 10.1016/j.ejmech.2019.111925.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejmech.2019.111925</ArticleId><ArticleId IdType="pmc">PMC6980694</ArticleId><ArticleId IdType="pubmed">31838328</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Z., Law W.-K., Wang D., Nie X., Sheng D., Song G., Guo K., Wei P., Ouyang P., Wong C.-W., et al. Synthesis and Discovery of Andrographolide Derivatives as Non-Steroidal Farnesoid X Receptor (FXR) Antagonists. RSC Adv. 2014;4:13533–13545. doi: 10.1039/C3RA46715E.</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/C3RA46715E</ArticleId></ArticleIdList></Reference><Reference><Citation>Dey A., Chen R., Li F., Maitra S., Hernandez J.-F., Zhou G.-C., Vincent B. Synthesis and Characterization of Andrographolide Derivatives as Regulators of ΒAPP Processing in Human Cells. Molecules. 2021;26:7660. doi: 10.3390/molecules26247660.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules26247660</ArticleId><ArticleId IdType="pmc">PMC8707718</ArticleId><ArticleId IdType="pubmed">34946739</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu J., He Y.Q., Yi L.N., Zan H., Kung H.F., He M.L. Viral Kinetics of Enterovirus 71 in Human Habdomyosarcoma Cells. World J. Gastroenterol. 2011;17:4135–4142. doi: 10.3748/wjg.v17.i36.4135.</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v17.i36.4135</ArticleId><ArticleId IdType="pmc">PMC3203367</ArticleId><ArticleId IdType="pubmed">22039330</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu K.X., Chu J.J.-H. Antiviral Screen Identifies EV71 Inhibitors and Reveals Camptothecin-Target, DNA Topoisomerase 1 as a Novel EV71 Host Factor. Antivir. Res. 2017;143:122–133. doi: 10.1016/j.antiviral.2017.04.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2017.04.008</ArticleId><ArticleId IdType="pubmed">28427827</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan J., Shen L., Wu J., Zou X., Gu J., Chen J., Mao L. Enterovirus A71 Proteins: Structure and Function. Front. Microbiol. 2018;9:286. doi: 10.3389/fmicb.2018.00286.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2018.00286</ArticleId><ArticleId IdType="pmc">PMC5826392</ArticleId><ArticleId IdType="pubmed">29515559</ArticleId></ArticleIdList></Reference><Reference><Citation>Murray K.E., Nibert M.L. Guanidine Hydrochloride Inhibits Mammalian Orthoreovirus Growth by Reversibly Blocking the Synthesis of Double-Stranded RNA. J. Virol. 2007;81:4572–4584. doi: 10.1128/JVI.02106-06.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02106-06</ArticleId><ArticleId IdType="pmc">PMC1900160</ArticleId><ArticleId IdType="pubmed">17301147</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider-Poetsch T., Ju J., Eyler D.E., Dang Y., Bhat S., Merrick W.C., Green R., Shen B., Liu J.O. Inhibition of Eukaryotic Translation Elongation by Cycloheximide and Lactimidomycin. Nat. Chem. Biol. 2010;6:209–217. doi: 10.1038/nchembio.304.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nchembio.304</ArticleId><ArticleId IdType="pmc">PMC2831214</ArticleId><ArticleId IdType="pubmed">20118940</ArticleId></ArticleIdList></Reference><Reference><Citation>Gunaseelan S., Wong K.Z., Min N., Sun J., Ismail N.K.B.M., Tan Y.J., Lee R.C.H., Chu J.J.H. Prunin Suppresses Viral IRES Activity and Is a Potential Candidate for Treating Enterovirus A71 Infection. Sci. Transl. Med. 2019;11:eaar5759. doi: 10.1126/scitranslmed.aar5759.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aar5759</ArticleId><ArticleId IdType="pubmed">31666401</ArticleId></ArticleIdList></Reference><Reference><Citation>Lv X., Qiu M., Chen D., Zheng N., Jin Y., Wu Z. Apigenin Inhibits Enterovirus 71 Replication through Suppressing Viral IRES Activity and Modulating Cellular JNK Pathway. Antivir. Res. 2014;109:30–41. doi: 10.1016/j.antiviral.2014.06.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2014.06.004</ArticleId><ArticleId IdType="pubmed">24971492</ArticleId></ArticleIdList></Reference><Reference><Citation>Swinney D.C. Phenotypic vs. Target-Based Drug Discovery for First-in-Class Medicines. Clin. Pharmacol. Ther. 2013;93:299–301. doi: 10.1038/clpt.2012.236.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/clpt.2012.236</ArticleId><ArticleId IdType="pubmed">23511784</ArticleId></ArticleIdList></Reference><Reference><Citation>Loureiro Damasceno J.P., Silva da Rosa H., Silva de Araújo L., Jacometti Cardoso Furtado N.A. Andrographis Paniculata Formulations: Impact on Diterpene Lactone Oral Bioavailability. Eur. J. Drug Metab. Pharmacokinet. 2022;47:19–30. doi: 10.1007/s13318-021-00736-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13318-021-00736-7</ArticleId><ArticleId IdType="pmc">PMC8609994</ArticleId><ArticleId IdType="pubmed">34816382</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Y., Wei H., Wang J., Wang W., Gao J. Synthesis of Andrographolide Analogues and Their Neuroprotection and Neurite Outgrowth-Promoting Activities. Bioorganic Med. Chem. 2019;27:2209–2219. doi: 10.1016/j.bmc.2019.04.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bmc.2019.04.025</ArticleId><ArticleId IdType="pubmed">31014564</ArticleId></ArticleIdList></Reference><Reference><Citation>Gong C., Xu C., Ji L., Wang Z. A Novel Semi-Synthetic Andrographolide Analogue A5 Inhibits Tumor Angiogenesis via Blocking the VEGFR2-P38/ERK1/2 Signal Pathway. Biosci. Trends. 2013;7:230–236. doi: 10.5582/bst.2013.v7.5.230.</Citation><ArticleIdList><ArticleId IdType="doi">10.5582/bst.2013.v7.5.230</ArticleId><ArticleId IdType="pubmed">24241173</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao X.-W., Fu H.-Z., Luo Y.-H., Wei X.-Y. Potential Anti-Angiogenic Sulfates of Andrographolide. J. Asian Nat. Prod. Res. 2013;15:809–818. doi: 10.1080/10286020.2013.803473.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/10286020.2013.803473</ArticleId><ArticleId IdType="pubmed">23777373</ArticleId></ArticleIdList></Reference><Reference><Citation>Wen T., Xu W., Liang L., Li J., Ding X., Chen X., Hu J., Lv A., Li X. Clinical Efficacy of Andrographolide Sulfonate in the Treatment of Severe Hand, Foot, and Mouth Disease (HFMD) Is Dependent upon Inhibition of Neutrophil Activation. Phytother. Res. 2015;29:1161–1167. doi: 10.1002/ptr.5361.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ptr.5361</ArticleId><ArticleId IdType="pubmed">25960284</ArticleId></ArticleIdList></Reference><Reference><Citation>Delvecchio R., Higa L., Pezzuto P., Valadão A., Garcez P., Monteiro F., Loiola E., Dias A., Silva F., Aliota M., et al. Chloroquine, an Endocytosis Blocking Agent, Inhibits Zika Virus Infection in Different Cell Models. Viruses. 2016;8:322. doi: 10.3390/v8120322.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v8120322</ArticleId><ArticleId IdType="pmc">PMC5192383</ArticleId><ArticleId IdType="pubmed">27916837</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar A., Liang B., Aarthy M., Singh S.K., Garg N., Mysorekar I.U., Giri R. Hydroxychloroquine Inhibits Zika Virus NS2B-NS3 Protease. ACS Omega. 2018;3:18132–18141. doi: 10.1021/acsomega.8b01002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsomega.8b01002</ArticleId><ArticleId IdType="pmc">PMC6312647</ArticleId><ArticleId IdType="pubmed">30613818</ArticleId></ArticleIdList></Reference><Reference><Citation>Roldan E.Q., Biasiotto G., Magro P., Zanella I. The Possible Mechanisms of Action of 4-Aminoquinolines (Chloroquine/Hydroxychloroquine) against SARS-Cov-2 Infection (COVID-19): A Role for Iron Homeostasis? Pharmacol. Res. 2020;158:104904. doi: 10.1016/j.phrs.2020.104904.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.phrs.2020.104904</ArticleId><ArticleId IdType="pmc">PMC7217799</ArticleId><ArticleId IdType="pubmed">32430286</ArticleId></ArticleIdList></Reference><Reference><Citation>Biot C., Daher W., Chavain N., Fandeur T., Khalife J., Dive D., De Clercq E. Design and Synthesis of Hydroxyferroquine Derivatives with Antimalarial and Antiviral Activities. J. Med. Chem. 2006;49:2845–2849. doi: 10.1021/jm0601856.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/jm0601856</ArticleId><ArticleId IdType="pubmed">16640347</ArticleId></ArticleIdList></Reference><Reference><Citation>Vishvakarma V.K., Nand B., Kumar V., Kumari K., Bahadur I., Singh P. Xanthene Based Hybrid Analogues to Inhibit Protease of Novel Corona Virus: Molecular Docking and ADMET Studies. Comput. Toxicol. 2020;16:100140. doi: 10.1016/j.comtox.2020.100140.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.comtox.2020.100140</ArticleId><ArticleId IdType="pmc">PMC7575443</ArticleId><ArticleId IdType="pubmed">33102987</ArticleId></ArticleIdList></Reference><Reference><Citation>Li F., Li X.-M., Sheng D., Chen S.-R., Nie X., Liu Z., Wang D., Zhao Q., Wang Y., Wang Y., et al. Discovery and Preliminary SAR of 14-Aryloxy-Andrographolide Derivatives as Antibacterial Agents with Immunosuppressant Activity. RSC Adv. 2018;8:9440–9456. doi: 10.1039/C8RA01063C.</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/C8RA01063C</ArticleId><ArticleId IdType="pmc">PMC9078697</ArticleId><ArticleId IdType="pubmed">35541862</ArticleId></ArticleIdList></Reference><Reference><Citation>Richter S., Parolin C., Palumbo M., Palu G. Antiviral Properties of Quinolone-Based Drugs. Curr. Drug Target-Infect. Disord. 2004;4:111–116. doi: 10.2174/1568005043340920.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1568005043340920</ArticleId><ArticleId IdType="pubmed">15180459</ArticleId></ArticleIdList></Reference><Reference><Citation>Tran Q.T.N., Tan W.S.D., Wong W.S.F., Chai C.L.L. Polypharmacology of Andrographolide: Beyond One Molecule One Target. Nat. Prod. Rep. 2021;38:682–692. doi: 10.1039/D0NP00049C.</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/D0NP00049C</ArticleId><ArticleId IdType="pubmed">33021616</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang C.-C., Duann Y.-F., Yen T.-L., Chen Y.-Y., Jayakumar T., Ong E.-T., Sheu J.-R. Andrographolide, a Novel NF-κB Inhibitor, Inhibits Vascular Smooth Muscle Cell Proliferation and Cerebral Endothelial Cell Inflammation. Acta Cardiol. Sin. 2014;30:308–315.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4804993</ArticleId><ArticleId IdType="pubmed">27122804</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin Y., Zhang R., Wu W., Duan G. Antiviral and Inflammatory Cellular Signaling Associated with Enterovirus 71 Infection. Viruses. 2018;10:155. doi: 10.3390/v10040155.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v10040155</ArticleId><ArticleId IdType="pmc">PMC5923449</ArticleId><ArticleId IdType="pubmed">29597291</ArticleId></ArticleIdList></Reference><Reference><Citation>Srikanth L., Sarma P.V.G.K. Andrographolide Binds to Spike Glycoprotein and RNA-Dependent RNA Polymerase (NSP12) of SARS-CoV-2 by in Silico Approach: A Probable Molecule in the Development of Anti-Coronaviral Drug. J. Genet. Eng. Biotechnol. 2021;19:101. doi: 10.1186/s43141-021-00201-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s43141-021-00201-7</ArticleId><ArticleId IdType="pmc">PMC8276218</ArticleId><ArticleId IdType="pubmed">34255214</ArticleId></ArticleIdList></Reference><Reference><Citation>Carpenter A.E., Jones T.R., Lamprecht M.R., Clarke C., Kang I.H., Friman O., Guertin D.A., Chang J.H., Lindquist R.A., Moffat J., et al. CellProfiler: Image Analysis Software for Identifying and Quantifying Cell Phenotypes. Genome Biol. 2006;7:R100. doi: 10.1186/gb-2006-7-10-r100.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/gb-2006-7-10-r100</ArticleId><ArticleId IdType="pmc">PMC1794559</ArticleId><ArticleId IdType="pubmed">17076895</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>